ClinicalTrials.gg

Biogen clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 549 studies whose lead sponsor is Biogen or one of 5 companies grouped under it. 28 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 16, 2026.

Our grouping of 6 registry names, not the registry’s. See them and correct one ↓

Compare Biogen with Boehringer Ingelheim and Novartis →

Pipeline: 11 programs

Each counted once: 11 with a study Biogen leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 5 phase-3 programs — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Biogen’s own registered studies; Biogen’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Biogen’s studies test, most open studies first — 62 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 62; every drug is on its own page, and each page lists its sponsors.

Coming up

15 of Biogen’s studies under way reach primary completion within a year, 7 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 1D
  3. J’27
  4. 2F
  5. 1M
  6. A
  7. 3M
  8. 2J
  9. 1J
  10. 1A
  11. 3S
  12. O
  13. 1N

The 12 nearest

Show 7 more

Add all 15 to your calendar (.ics) → With an account.

All 549 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now285%Recruiting 21 · Not yet recruiting 4 · Enrolling by invitation 3
  • Under way, not recruiting193%
  • Completed38370%
  • Stopped early11521%Terminated 93 · Withdrawn 22
  • Status unknown or other41%Approved for marketing 2 · No longer available 2

Phase

Where

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 3915
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 1626

By the year each study started; 57 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Biogen.

  • Biogen
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    512 studies
  • Apellis Pharmaceuticals, Inc.
    Acquired — became part of Biogen, May 14, 2026 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    28 studies →
  • HI-Bio, A Biogen Company
    Acquired — became part of Biogen, Jul 2, 2024 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    5 studies →
  • Convergence Pharmaceuticals
    Acquired — became part of Biogen, Feb 12, 2015 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • Stromedix, Inc.
    Acquired — became part of Biogen, Mar 8, 2012 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →
  • Reata, a wholly owned subsidiary of Biogen
    Acquired — became part of Biogen, Sep 26, 2023 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Focus areas

Conditions Biogen leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 549. Browse all 549 →